Joint IP Working Group Sample Clauses
The Joint IP Working Group clause establishes a collaborative committee or team composed of representatives from the parties involved, tasked with overseeing and managing intellectual property (IP) matters arising from their joint activities. This group typically meets regularly to discuss issues such as ownership, protection, and commercialization of jointly developed IP, and may be responsible for making recommendations or decisions regarding patent filings, licensing, or dispute resolution. Its core practical function is to provide a structured forum for coordinated decision-making, ensuring that both parties' interests are represented and that IP-related issues are addressed efficiently and transparently.
Joint IP Working Group. Promptly following the Effective Date, the Parties shall establish a joint working group consisting of at least one (1) designee of Adamas and at least one (1) designee of Forest, each of which shall have experience in the prosecution, enforcement and defense of intellectual property rights in the pharmaceutical field (the “Joint IP Working Group” or “JIPWG”). Each Party may change its designee(s) on the JIPWG upon written notice to the other Party. The JIPWG shall be responsible for coordinating all material activities and material communications relating to the prosecution, maintenance and enforcement of the Adamas Memantine Patent Rights in the Territory and for coordinating all other material communications between the Parties with respect to the Adamas Patent Rights that are not Adamas Memantine Patent Rights and the Forest Patent Rights. The JIPWG shall strive to reach consensus with respect to such matters; provided, however, that, in the event that consensus cannot be reached, (a) subject to any applicable provisions of Section 7.3, [*] the applicable Adamas Patent Right, including any Adamas Memantine Patent Right, or Forest Patent Right, as the case may be, shall [*] with respect to such prosecution and maintenance and (b) [*] any Adamas IP Infringement Claim or Invalidity Claim shall [*] with respect to such action; in each case as more fully described in, and subject to, this ARTICLE VII.
Joint IP Working Group. Promptly following the Effective Date, the Parties shall each designate one representative with the requisite experience to make decisions on behalf of the applicable Party with respect to the prosecution, enforcement and defense of intellectual property rights in the pharmaceutical field (each, an “IP Representative”). From time to time, each Party may replace its IP Representative on written notice to the other Party. The IP Representatives shall be responsible for coordinating activities and communications relating to the prosecution, maintenance and enforcement of the ▇▇▇▇▇▇▇ Patents, as described in this ARTICLE 7.
Joint IP Working Group. The Parties shall establish a joint intellectual property working group (the “Joint IP Working Group”) within [**] following the Effective Date. The Joint IP Working Group will be responsible for providing the JGC and the Parties with guidance with respect to matters relating to (i) the preparation, filing, prosecution and maintenance of the Collaboration Patent Rights, Joint Patent Rights, the Voyager Research Antibody Patent Rights, and the AbbVie Research Antibody Patent Rights, (ii) freedom-to-operate matters, (iii) discussing any challenges to any Third Party’s Patent Rights that may Cover any Selected Research Compounds, Selected Research Products, Licensed Compounds or Licensed Products; and (iv) advising the JGC regarding which of the In-License Agreements are relevant to any Selected Research Compound(s) or Selected Research Product(s). The Joint IP Working Group will report to the JGC.
Joint IP Working Group. [***] the Parties shall establish a joint intellectual property working group (the “JIPWG”), which shall be a Working Group of the JSC (except with respect to any trademark matters, with respect to which the JIPWG shall be a Working Group of the JCC), to provide a forum for the Parties to discuss and coordinate with respect to the Parties’ activities and responsibilities under Article 11 with respect to the JIPWG Oversight Patents, and to make decisions with respect to the JIPWG Oversight Patents that are allocated to the JIPWG as set forth in Article 11. The JIPWG shall be comprised of at least one (1) representative from each Party (provided that in the event that any Competitive Infringement as specified in Article 11 may arise or has arisen, the JIPWG shall, for purposes of discussing and making decisions with respect to such Competitive Infringement as set forth in Article 11, also include one (1) or more members from each Party competent to address matters relating to initiation, prosecution and settlement of such Competitive Infringement). The representatives, if any, for trademark and copyright matters shall include qualified lawyers in good standing in their relevant jurisdictions, and for all other intellectual property matters shall be patent attorneys registered and in good standing with the United States Patent and Trademark Office (or equivalent patent office in the European Union). Subject to the immediately preceding sentence, a Party may change one or more of its JIPWG representatives from time to time in its sole discretion, effective upon written notice to the other Party of such change, which notice may be given by e-mail sent to the other Party’s representatives of the JIPWG and the JSC. The JIPWG shall meet (either in person or by audio or video conference) as often as is necessary as well as upon the reasonable request of either Party. Without limiting the foregoing, the JSC may make further changes to the JIPWG (including its size, purpose, procedures and scope of responsibilities) on an as-needed basis, so long as the changes are consistent with the provisions of Article 11. The JIPWG shall discuss those matters as set forth in Article 11, and shall make decisions as allocated to the JIPWG as set forth in Article 11, including:
(a) discussing any issues regarding ownership of (i) Know-How first discovered, generated, created, conceived or otherwise made by or on behalf of a Party or any of its Affiliates, whether solely or jointly ...
Joint IP Working Group. Promptly following the Effective Date, the Parties shall establish a joint working group consisting of at least one (1) designee of Adamas and at least one (1) designee of Forest, each of which shall have experience in the prosecution, enforcement and defense of intellectual property rights in the pharmaceutical field (the “Joint IP Working Group” or “JIPWG”). Each Party may change its designee(s) on the JIPWG upon written notice to the other Party. The JIPWG shall be responsible for coordinating all material activities and material [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. communications relating to the prosecution, maintenance and enforcement of the Adamas Memantine Patent Rights in the Territory and for coordinating all other material communications between the Parties with respect to the Adamas Patent Rights that are not Adamas Memantine Patent Rights and the Forest Patent Rights. The JIPWG shall strive to reach consensus with respect to such matters; provided, however, that, in the event that consensus cannot be reached, (a) subject to any applicable provisions of Section 7.3, [ * ] the applicable Adamas Patent Right, including any Adamas Memantine Patent Right, or Forest Patent Right, as the case may be, shall [ * ] with respect to such prosecution and maintenance and (b) [ * ] any Adamas IP Infringement Claim or Invalidity Claim shall [ * ] with respect to such action; in each case as more fully described in, and subject to, this ARTICLE VII.
Joint IP Working Group. Within fifteen (15) days after the Effective Date, the Parties shall establish a joint working group consisting of at least one (1) designee of GSK and at least one (1) designee of NeuroMetrix, each of which shall have experience in the protection, prosecution/registration and enforcement of intellectual property rights in the medical device field (the “Joint IP Working Group”). Each Party may change its designee(s) on the Joint IP Working Group upon written notice to the other Party. The Joint IP Working Group shall be responsible for coordinating all material activities and material communications relating to (a) the preparation, filing, prosecution, maintenance, defense, infringement and enforcement of Arising Intellectual Property Rights under Section 7.2 and Section 7.3 and for coordinating all other material communications between the Parties with respect to the Arising Intellectual Property Rights and (b) the filing of patent applications (e.g. PCT applications) and design applications at the end of the priority periods established by the respective US Provisionals and US design patent applications in the Excluded Territory Patents (as defined in the Asset Purchase Agreement). The Joint IP Working Group shall strive to reach consensus with respect to such matters; provided, however, that, in the event that consensus cannot be reached, (a) subject to any applicable provisions of Section 7.2, the Party [***]
Joint IP Working Group. Promptly following the Effective Date, the Parties shall establish a joint working group consisting of at least one (1) designee of vTv and at least one (1) designee of Huadong, each of which shall have experience in the prosecution and enforcement of intellectual property rights in the pharmaceutical field (the “Joint IP Working Group” or “JIPWG”). Each Party may change its designee(s) on the JIPWG upon written notice to the other Party. The JIPWG shall be responsible for coordinating all activities and communications relating to the prosecution, maintenance and enforcement of Patent Rights and shall communicate and meet on an ad hoc, as-needed basis. The JIPWG shall strive to reach consensus; provided, that in exercising its rights under this ARTICLE VII, each Party shall implement or incorporate, absent a substantial reason to the contrary, all reasonable comments of the other Party.